This bill amends several sections of the General Laws in Rhode Island to mandate coverage for the treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute onset neuropsychiatric syndrome. The amendments specify that every group health insurance contract or policy issued or renewed on or after January 1, 2023, must include this coverage, which encompasses treatments such as intravenous immunoglobulin therapy.

The bill clarifies that these healthcare benefits apply to services delivered within Rhode Island, while requiring coverage for these benefits outside the state if necessary services are unavailable within the state.

Significantly, the bill removes the previous sunset provision that would have repealed this coverage on December 31, 2025, thereby ensuring that the mandated coverage remains in effect indefinitely. Additionally, it updates the terminology from "immunoglobin" to "immunoglobulin" for accuracy. The bill is designed to enhance access to necessary treatments for affected children and will take effect upon passage.

Statutes affected:
5625: 27-18-90, 27-19-82, 27-20-78, 27-41-95
5625  SUB A: 27-18-90, 27-19-82, 27-20-78, 27-41-95